Skip to content

STAT+: Are analysts too quick to gloss over Lilly’s liver case? · Stateside Daily

Stateside DailyAll America

Search Get alerts

Home›Health›1 sources

Health · 1 sources covering this

STAT+: Are analysts too quick to gloss over Lilly’s liver case?

Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·15h ago
STAT+: Are analysts too quick to gloss over Lilly’s liver case?
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
Read at STAT →

More from Health

NPRLean L·8h ago

Cruise ship with hantavirus may have seen a rare occurrence: humans infecting humans

STAT·10h ago

STAT+: Did AI really beat doctors at diagnosis?

Daily briefing

Stateside Daily in your inbox

The 5 stories from all america you actually need to read. Once a day, no fluff. Unsubscribe in one click.

Stateside Daily

About
Careers
Contact
Editorial standards

Sections

Politics
Business
Markets
Technology
Ai

NPRLean L·10h ago

Midwives saved his mom's life -- and inspired him to pursue the profession

STAT·12h ago

STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing

Reader

Notifications
Bookmarks
Search
Personal feed

Trust & legal

Corrections
Privacy
Terms
Security

Across the network

Hindustan Sphere
All India in one feed

© 2026 Stateside Daily. All headlines are sourced from third-party publishers; we never republish article bodies.

All America